ClinicalTrials.gg

Program

TQD3524

A development code.

In Sino Biopharmaceutical's pipeline, 多粘菌素E2. Its studies are mostly in Pneumonia, Bacterial, led by Sino Biopharmaceutical.

Furthest: phase 2, since Mar 27, 20262 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical21 open or runningphase 2since Mar 27, 2026Jul 23, 2024Jul 2027phase 2 · NCT07512596
  • Named in Sino Biopharmaceutical’s own pipeline as TQD3524, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2024First study: phase 1 study in Multi-resistant Gram-negative Bacteria Cause InfectionFirst studyNCT06522945 · 48 enrolled · China
  2. Mar 27, 2026Phase 2 study in Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial PneumoniaPhase 2 reachedNCT07512596 · 48 planned · China

Ahead

  1. Jul 2027Primary completion: phase 2 study in Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial PneumoniaNCT07512596

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“多粘菌素E2”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07512596Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia · China2RecruitingJul 202748
NCT06522945Multi-resistant Gram-negative Bacteria Cause Infection · China1CompletedDec 18, 202548

How it is read

Names in the registry

  • “TQD3524”, 7 entries

Codes read as this program: TQD3524.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.